Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0201

Scientific exchange · Dr. Ulrich Tanaka

24 Mar 2026 · In person · Dr. Ulrich Tanaka, Peter MacCallum Cancer Centre · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0201—

Capture insight from this engagement

Location: Peter MacCallum Cancer Centre
Therapeutic area: Neurology
Country: Australia
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Drug interactions
Switching between CGRP agents

Scientific content used

LMV persistence data summary

Questions raised

Is there guidance on switching from a monoclonal antibody?

Notes

Scientific exchange with general neurologist at Peter MacCallum Cancer Centre. Discussed drug interactions, switching between cgrp agents.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 2
Depth of exchange: 4
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0201

Audit history (0)

All create, update and approval events for this record

No audit events in sample data